JUL 17, 2017 6:48 PM PDT

Putting A Target On Cancer's Back

WRITTEN BY: Kara Marker

Scientists are putting a target on cancer’s back, and immune cells are being trained to track down and kill that target. In a new study from the University of Texas M.D. Anderson Cancer Center, researchers describe how they used immune cells acquired from donated umbilical cord blood to be trained and suited up to identify leukemia and lymphoma cancer cells.

 

A Wright's stained peripheral blood smear showing chronic lymphocytic leukemia (CLL). The lymphocytes with the darkly staining nuclei and scant cytoplasm are the CLL cells.

 

Natural killer (NK) cells derived from cord blood are capable of targeting cancer on their own, but a new method of modifying these cells makes them even better at getting the job done. First, they are genetically engineered to be particularly persistent on finding and killing cancer. Lacing their genome with an immune chemical called interleukin (IL) 15 accomplishes this.

Next, a chimeric antigen receptor (CAR) focuses NK cells on B cell malignancies, such as surface protein CD19. This, says study researcher Elizabeth Shpall, MD, turns the NK cells into “guided missiles.” Lastly, researchers included a “self-destruct gene,” installed to protect already-weakened cancer patients against an excessive inflammatory response.

Results from studies in cell lines and mouse model showed that the modified NK cells destroyed tumors better and longer than normal NK cells. A unique phase I/II human clinical trial for patients with relapsed or resistant B cell cancers, chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), and non-Hodgkin lymphoma, began in June. Scientists will assess the potential of the newly modified NK cells in the setting of human cancer, the ultimate test.

"Natural killer cells are the immune system's most potent killers, but they are short-lived and cancers manage to evade a patient's own NK cells to progress," explained Katy Rezvani, MD, PhD. "Our cord-blood derived NK cells… are designed to address these challenges.” Indeed, Rezvani’s modified NK cells have been shown to persist for months instead of just a few weeks.

Benefits of using this approach in NK cells versus T cells

There is a risk of graft versus host disease in CAR T cells if cells are taken from a donor. T cells can be taken from the patient, but the process of transforming them into CAR T cells takes several weeks. So far, CAR NK cells from donated cord blood have shown no risk of graft versus host disease.

The MD Anderson Cord Blood Bank, found and directed by Shpall, now has 26,000 cords stored. The present study was published in the journal Leukemia.

Sources: University of Texas M.D. Anderson Cancer Center, Nature Immunology

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 10, 2020
Cancer
Pancreatic cancer patients see hope in this newly developed drug
SEP 10, 2020
Pancreatic cancer patients see hope in this newly developed drug
A new drug developed by researchers at the University of Sheffield hopes to improve life expectancy and quality of life ...
SEP 12, 2020
Cancer
Treating cancer with the botanical andrographis
SEP 12, 2020
Treating cancer with the botanical andrographis
A study from City of Hope published in the journal Carcinogenesis reports that the use of the natural botanical And ...
OCT 22, 2020
Cancer
Cancer cells don't like crowded spaces
OCT 22, 2020
Cancer cells don't like crowded spaces
Researchers collaborating from St. Anna Children's Cancer Research Institute Vienna, King's College London, Inst ...
NOV 02, 2020
Cancer
Using an Anti-Malarial Drug to Fight Cancer
NOV 02, 2020
Using an Anti-Malarial Drug to Fight Cancer
Modern pharmaceutical companies spend billions of dollars and years of time developing the next big drug. What if they d ...
NOV 18, 2020
Cancer
Could Targeting the Proteasome be Effective Against Cancer?
NOV 18, 2020
Could Targeting the Proteasome be Effective Against Cancer?
One of the trickiest things about anti-cancer drug design is targeting. Today, most drugs on the market target critical ...
NOV 21, 2020
Cancer
Hospital patients want processed meats removed from hospital menus
NOV 21, 2020
Hospital patients want processed meats removed from hospital menus
A survey published in the Journal of Hospital Management and Health Policy reports that most patients are in agreem ...
Loading Comments...